Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 10/2011

01-10-2011 | Thoracic Oncology

Lymphatic Vessel Invasion is a Significant Prognostic Indicator in Stage IA Lung Adenocarcinoma

Authors: Kazuhito Funai, MD, PhD, Haruhiko Sugimura, MD, PhD, Toyohiko Morita, MD, PhD, Yasumasa Shundo, MD, Kei Shimizu, MD, Norihiko Shiiya, MD, PhD

Published in: Annals of Surgical Oncology | Issue 10/2011

Login to get access

Abstract

Background

A radical resection is considered to be the most effective treatment for resectable non-small cell lung cancer. However, even when resected in early stages (T1aN0, T1bN0) up to 20% of patients will experience recurrence. The aim of this retrospective study was to evaluate the prognostic influence of lymphatic vessel invasion (LVI) in stage IA adenocarcinoma patients.

Methods

From January 1983 to June 2003, a total of 229 consecutive patients with pT1a or T1b N0 M0 lung adenocarcinoma who had undergone radical resection and lymph node dissection were retrospectively reviewed. Sections stained by the hematoxylin-eosin and the Elastica van Gieson method were examined for the presence of LVI. The overall survival was estimated using the Kaplan-Meier method, log-rank test, and the Cox proportional hazards analysis.

Results

The median follow-up was 81 months. A total of 143 patients (62%) were able to be diagnosed with regard to the presence of LVI, while information was not provided for 86 patients (38%), who were therefore excluded from the study. LVI was noted in 22 of the evaluable patients (15%) and was not seen in the other 121 patients (85%). The 5-year overall survival rate of the LVI-negative group and the LVI-positive group was 94.5 and 70.9%, respectively (P = .003). A multivariate analysis revealed LVI to be an independent predictive factor (hazard ratio: 0.202; P = .001).

Conclusion

LVI is an independent poor prognostic factor in patients with pathologic stage IA adenocarcinoma. The T1a and T1b patients with LVI both might benefit from adjuvant chemotherapy.
Literature
1.
Poleri C, Morero JL, Nieva B, Vazquez MF, Rodriguez C, de Titto E, et al. Risk of recurrence in patients with surgically resected stage I non small cell lung cancer. Chest. 2003;123:1858–67.PubMedCrossRef
2.
Sawabata N, Asamura H, Goya T, Mori M, Nakanishi Y, Eguchi K, et al. Japanese Lung Cancer Registry Study: First prospective enrollment of a large number of surgical and nonsurgical cases in 2002. J Thorac Oncol. 2010;5:1369–75.PubMedCrossRef
3.
Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, et al; Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004;350:1713–21.PubMedCrossRef
4.
Goldstraw P. Staging Manual in Thoracic Oncology. Denver: IASLC, 2009.
5.
Travis WD, Brambilla E, Muller-Hermelink H, Harris CC. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004.
6.
Tsuchiya T, Akamine S, Muraoka M, Kamohara R, Tsuji K, Urabe S, et al. Stage IA nonsmall cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer. 2007;56:341–8.PubMedCrossRef
7.
Gabor S, Renner H, Popper H, Anegg U, Sankin O, Matzi V, et al. Invasion of blood vessels significant prognostic factor in radically resected T1-3N0M0 non-small-cell lung cancer. Eur J Cardiothorac Surg. 2004;25:439–42.PubMedCrossRef
8.
Goldstein NS, Mani A, Chmielewski G, Welsh R, Pursel S. Prognostic factors in T1 N0 M0 adenocarcinomas and bronchioloalveolar carcinomas of the lung. Am J Clin Pathol. 1999;112:391–402.PubMed
9.
Shoji F, Haro A, Yoshida T, Ito K, Morodomi Y, Yano T, et al. Prognostic significance of intratumoral blood vessel invasion in pathologic stage IA non-small cell lung cancer. Ann Thorac Surg. 2010;89:864–9.PubMedCrossRef
10.
Min KH, Park SJ, Lee KS, Hwang SH, Kim SR, Moon H, et al. Clinical usefulness of D2-40 in non-small cell lung cancer. Lung. 2011;189:57–63.PubMedCrossRef
11.
Kadota K, Huang CL, Liu D, Nakashima N, Yokomise H, Ueno M, et al. The clinical significance of the tumor cell D2-40 immunoreactivity in non-small cell lung cancer. Lung Cancer. 2010;70:88–93.PubMedCrossRef
12.
Iwakiri S, Nagai S, Katakura H, Takenaka K, Date H, Wada H, et al. D2-40-positive lymphatic vessel density is a poor prognostic factor in squamous cell carcinoma of the lung. Ann Surg Oncol. 2009;16:1678–85.PubMedCrossRef
13.
Faoro L, Hutto JY, Salgia R, El-Zayaty SA, Ferguson MK, Cheney RT, et al. Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma. Arch Pathol Lab Med. 2008;132:1882–8.PubMed
14.
Igai H, Matsuura N, Tarumi S, Chang SS, Misaki N, Go T, et al. Clinicopathological study of p-T1aN0M0 non-small-cell lung cancer, as defined in the seventh edition of the TNM classification of malignant tumors. Eur J Cardiothorac Surg. 2010. doi:10.​1016/​j.​ejcts.​2010.​09.​008.
Metadata
Title
Lymphatic Vessel Invasion is a Significant Prognostic Indicator in Stage IA Lung Adenocarcinoma
Authors
Kazuhito Funai, MD, PhD
Haruhiko Sugimura, MD, PhD
Toyohiko Morita, MD, PhD
Yasumasa Shundo, MD
Kei Shimizu, MD
Norihiko Shiiya, MD, PhD
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 10/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-1729-9

Other articles of this Issue 10/2011

Annals of Surgical Oncology 10/2011 Go to the issue

Healthcare Policy and Outcomes

The Significance of PITX2 Overexpression in Human Colorectal Cancer

Hepatobiliary Tumors

Clinical Scoring Systems for Stratifying Risk after Resection of Hepatic Colorectal Metastases: Still Relevant?

Healthcare Policy and Outcomes

Adrenalectomy in Older Americans has Increased Morbidity and Mortality: An Analysis of 6,416 Patients

Urologic Oncology

Radical Prostatectomy Versus External-Beam Radiotherapy for Localized Prostate Cancer: Long-Term Effect on Biochemical Control—In Search of the Optimal Treatment

Endocrine Tumors

Predictive Value of Cytologic Atypia in Indeterminate Thyroid Fine-Needle Aspirate Biopsies

Pancreatic Tumors

Pancreas-Protocol Imaging at a High-Volume Center Leads to Improved Preoperative Staging of Pancreatic Ductal Adenocarcinoma